PD 217014

Drug Profile

PD 217014

Alternative Names: PD-217,014

Latest Information Update: 12 Sep 2008

Price : $50

At a glance

  • Originator Pfizer
  • Class Aminobutyric acids; Anti-inflammatories; Heterocyclic bicyclo compounds; Irritable bowel syndrome therapies; Urologics
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Irritable bowel syndrome; Overactive bladder; Postherpetic neuralgia

Most Recent Events

  • 07 Jan 2005 Phase-II clinical trials in Overactive bladder in United Kingdom (unspecified route)
  • 31 Jan 2004 Phase-II clinical trials in Irritable bowel syndrome in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top